Aesica Appoints New Director
Leading pharmaceutical manufacturer, Aesica, has appointed Kevin Cook as Managing Director of its Active Pharmaceutical Ingredient (API) Business Unit.
Kevin will be based out of the company’s Head Office at Quorum Business Park and will lead the business development team to promote the company’s API service offering and extensive capabilities. His key area of focus will be to significantly grow the API business unit through the introduction of new product lines utilising existing assets and expansion through acquisition into India, Asia and further expansion across the US.
With over 25 years experience in the pharmaceutical manufacturing industry Kevin has worked with many companies growing and expanding their business base and supporting a number of successful mergers and acquisitions. Prior to joining Aesica, Kevin worked for Rhodia Pharma Solutions as Industrial Director and Shasun Pharma Solutions as President.
Speaking of his appointment Kevin says: “Aesica has a proven track record in providing primary and secondary contract manufacturing services to the highest possible standards and to be leading the API team is a real privilege. I am passionate about delivering excellence across all aspects of service provision and will work to build on Aesica’s established values so that the company is recognised as the primary partner of choice within the industry.
It’s Aesica’s vision to become the leading global supplier of Active Pharmaceutical Ingredients and Formulated Products and I hope that my expertise will play a crucial role in helping the company to achieve this objective. I am looking forward to driving the API business unit forward while integrating with the Formulated Products and R5 Formulation Development units to fully promote Aesica’s service proposition and demonstrate our ability to manufacture from the initial clinical trial stage through to full commercial delivery.”
Dr. Robert Hardy, Chief Executive, Aesica, adds: “Kevin’s appointment is strategically important to the business as we continue to enhance our global presence and reputation while expanding into new markets with a focus on increasing our US market share and establishing a presence in India. Our recent acquisition of three UCB sites in Europe demonstrates our commitment to enhancing our full service offering and will enable the business development team to further enhance and strengthen our unique service proposition.”
Aesica supplies contract development and contract manufacturing services for Formulated Products and Active Pharmaceutical Ingredients to a host of the world’s leading pharmaceutical companies and emerging biotechnology organisations.